 Flavia Hoyte
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 28 | 2025 | 2293 | 3.360 |
Why?
| | Anti-Asthmatic Agents | 17 | 2025 | 393 | 3.050 |
Why?
| | Biological Products | 10 | 2025 | 215 | 2.770 |
Why?
| | Rhinitis, Allergic | 4 | 2024 | 38 | 1.260 |
Why?
| | Sinusitis | 4 | 2024 | 221 | 1.230 |
Why?
| | Nasal Polyps | 3 | 2024 | 59 | 1.220 |
Why?
| | Hypersensitivity | 3 | 2024 | 257 | 1.130 |
Why?
| | Rhinitis | 3 | 2024 | 158 | 1.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 805 | 1.000 |
Why?
| | Remission Induction | 2 | 2025 | 288 | 0.900 |
Why?
| | Adrenal Cortex Hormones | 9 | 2025 | 556 | 0.860 |
Why?
| | Bronchodilator Agents | 3 | 2023 | 248 | 0.780 |
Why?
| | Curcumin | 1 | 2022 | 29 | 0.770 |
Why?
| | Urticaria | 1 | 2022 | 39 | 0.760 |
Why?
| | Pancreatitis | 2 | 2012 | 132 | 0.710 |
Why?
| | Respiratory Tract Diseases | 2 | 2012 | 187 | 0.670 |
Why?
| | Desensitization, Immunologic | 2 | 2018 | 94 | 0.670 |
Why?
| | Allergens | 2 | 2024 | 408 | 0.640 |
Why?
| | Aspirin | 3 | 2018 | 387 | 0.640 |
Why?
| | Sublingual Immunotherapy | 1 | 2018 | 5 | 0.600 |
Why?
| | Exhalation | 1 | 2018 | 39 | 0.590 |
Why?
| | Nebulizers and Vaporizers | 3 | 2025 | 86 | 0.480 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 2 | 2025 | 37 | 0.460 |
Why?
| | Nitric Oxide | 2 | 2024 | 915 | 0.450 |
Why?
| | Anti-Allergic Agents | 1 | 2014 | 46 | 0.430 |
Why?
| | Immunoglobulin E | 3 | 2024 | 342 | 0.420 |
Why?
| | Histamine | 3 | 2022 | 67 | 0.420 |
Why?
| | Severity of Illness Index | 6 | 2025 | 2836 | 0.420 |
Why?
| | Skin Tests | 2 | 2024 | 101 | 0.410 |
Why?
| | Voice Disorders | 1 | 2012 | 26 | 0.400 |
Why?
| | Vocal Cords | 1 | 2012 | 32 | 0.400 |
Why?
| | Administration, Inhalation | 5 | 2025 | 683 | 0.370 |
Why?
| | Double-Blind Method | 4 | 2024 | 1985 | 0.370 |
Why?
| | Muscarinic Antagonists | 2 | 2025 | 28 | 0.370 |
Why?
| | Histamine Antagonists | 1 | 2011 | 21 | 0.370 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2011 | 23 | 0.360 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2011 | 29 | 0.360 |
Why?
| | Humans | 37 | 2025 | 137294 | 0.350 |
Why?
| | Eosinophils | 5 | 2025 | 332 | 0.340 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 27 | 0.340 |
Why?
| | Quality of Life | 7 | 2025 | 2885 | 0.300 |
Why?
| | Formoterol Fumarate | 2 | 2025 | 7 | 0.290 |
Why?
| | Cost of Illness | 2 | 2024 | 303 | 0.280 |
Why?
| | Treatment Outcome | 7 | 2025 | 10800 | 0.270 |
Why?
| | Practice Guidelines as Topic | 3 | 2024 | 1577 | 0.260 |
Why?
| | Albuterol | 2 | 2023 | 110 | 0.240 |
Why?
| | Chronic Disease | 4 | 2024 | 1788 | 0.240 |
Why?
| | Skin | 2 | 2022 | 751 | 0.240 |
Why?
| | Allergy and Immunology | 1 | 2024 | 43 | 0.220 |
Why?
| | Geography | 1 | 2024 | 198 | 0.210 |
Why?
| | Drug Therapy, Combination | 3 | 2025 | 1063 | 0.200 |
Why?
| | Budesonide | 2 | 2023 | 89 | 0.190 |
Why?
| | Biomarkers | 3 | 2024 | 4164 | 0.190 |
Why?
| | Adrenergic beta-Agonists | 2 | 2025 | 133 | 0.180 |
Why?
| | Bayes Theorem | 1 | 2022 | 401 | 0.170 |
Why?
| | Cross-Over Studies | 1 | 2022 | 562 | 0.170 |
Why?
| | Aged | 8 | 2025 | 23851 | 0.160 |
Why?
| | Adult | 12 | 2025 | 37724 | 0.160 |
Why?
| | Male | 12 | 2025 | 67560 | 0.150 |
Why?
| | Female | 13 | 2025 | 73052 | 0.150 |
Why?
| | Child | 7 | 2025 | 21999 | 0.140 |
Why?
| | Biofeedback, Psychology | 1 | 2018 | 37 | 0.140 |
Why?
| | Middle Aged | 8 | 2025 | 33310 | 0.140 |
Why?
| | Mastocytosis, Systemic | 1 | 2017 | 8 | 0.140 |
Why?
| | Dystonia | 1 | 2017 | 25 | 0.140 |
Why?
| | Movement Disorders | 1 | 2017 | 59 | 0.130 |
Why?
| | Registries | 4 | 2025 | 2016 | 0.130 |
Why?
| | Administration, Oral | 2 | 2025 | 812 | 0.130 |
Why?
| | Omalizumab | 1 | 2016 | 51 | 0.130 |
Why?
| | Mast Cells | 1 | 2017 | 147 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2024 | 7607 | 0.120 |
Why?
| | Young Adult | 4 | 2024 | 13163 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2018 | 498 | 0.110 |
Why?
| | Heart Rate | 1 | 2018 | 823 | 0.110 |
Why?
| | Adolescent | 5 | 2024 | 21499 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1237 | 0.100 |
Why?
| | Comorbidity | 3 | 2024 | 1624 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2113 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 627 | 0.090 |
Why?
| | Receptors, Histamine | 1 | 2011 | 5 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 60 | 0.090 |
Why?
| | Administration, Intranasal | 1 | 2011 | 90 | 0.090 |
Why?
| | Pregnancy | 2 | 2016 | 6743 | 0.090 |
Why?
| | Medication Adherence | 1 | 2014 | 468 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 324 | 0.080 |
Why?
| | United States | 2 | 2024 | 14742 | 0.080 |
Why?
| | Drug Combinations | 2 | 2023 | 344 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1464 | 0.080 |
Why?
| | Age Factors | 1 | 2016 | 3297 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1484 | 0.070 |
Why?
| | Algorithms | 1 | 2014 | 1692 | 0.060 |
Why?
| | Disease Progression | 2 | 2022 | 2752 | 0.060 |
Why?
| | Ethanolamines | 1 | 2023 | 17 | 0.050 |
Why?
| | Cohort Studies | 2 | 2024 | 5726 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 331 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 47 | 0.050 |
Why?
| | Age of Onset | 1 | 2024 | 519 | 0.050 |
Why?
| | Steroids | 1 | 2023 | 168 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 105 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1260 | 0.050 |
Why?
| | Precision Medicine | 1 | 2025 | 428 | 0.040 |
Why?
| | Prospective Studies | 2 | 2023 | 7595 | 0.040 |
Why?
| | Seasons | 1 | 2023 | 545 | 0.040 |
Why?
| | Animals | 1 | 2022 | 36862 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1355 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 890 | 0.040 |
Why?
| | Carbidopa | 1 | 2017 | 4 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2850 | 0.040 |
Why?
| | Myoclonus | 1 | 2017 | 15 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2017 | 41 | 0.030 |
Why?
| | Levodopa | 1 | 2017 | 31 | 0.030 |
Why?
| | Diphenhydramine | 1 | 2017 | 37 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 350 | 0.030 |
Why?
| | Electroencephalography | 1 | 2018 | 433 | 0.030 |
Why?
| | Scoliosis | 1 | 2017 | 215 | 0.030 |
Why?
| | Dopamine | 1 | 2017 | 303 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 826 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2018 | 762 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5436 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2836 | 0.020 |
Why?
|
|
Hoyte's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|